Industry News
GRF Announces Record $2.5M Grant for Glaucoma Research

The Glaucoma Research Foundation (GRF) announced an unprecedented $2.5 million allocation in annual ...

read more
GRF Announces Record $2.5M Grant for Glaucoma Research
March 18, 2024
OcuTerra’s Nesvategrast Falls Short in Phase 2 Trial for Diabetic Retinopathy

OcuTerra Therapeutics' phase 2 trial for nesvategrast, an eye drop for diabetic retinopathy, failed ...

read more
OcuTerra’s Nesvategrast Falls Short in Phase 2 Trial for Diabetic Retinopathy
March 18, 2024
Pandorum Technologies Secures $11 Million for Corneal Blindness Treatment

Pandorum Technologies, a pioneering startup in the field of Tissue Engineering and Regenerative Medi...

read more
Pandorum Technologies Secures $11 Million for Corneal Blindness Treatment
March 18, 2024
MediPrint Ophthalmics Completes Drug-Eluting Contact Lens Study for Glaucoma

MediPrint Ophthalmics has successfully completed its SIGHT-2 phase 2b study, showcasing the efficacy...

read more
MediPrint Ophthalmics Completes Drug-Eluting Contact Lens Study for Glaucoma
March 12, 2024
Ravegza, Lucentis Biosimilar, Granted Marketing Authorization in Saudi Arabia

Formycon AG and MS Pharma announced that their product, Ravegza (FYB201), a biosimilar to Lucentis (...

read more
Ravegza, Lucentis Biosimilar, Granted Marketing Authorization in Saudi Arabia
March 12, 2024
Study: Eylea HD Achieves Key Milestone in Wet AMD and DME Treatment

Regeneron Pharmaceuticals announced that The Lancet has published the one-year results of the pivota...

read more
Study: Eylea HD Achieves Key Milestone in Wet AMD and DME Treatment
March 11, 2024
SDC Transfers Ophthalmic Biometric Division to Ora Inc.

Statistics & Data Corporation (SDC) has made a pivotal decision to hand over its ophthalmic biometri...

read more
SDC Transfers Ophthalmic Biometric Division to Ora Inc.
March 08, 2024
Vital Tears Names Joseph Tauber, MD as Chief Medical Officer

Vital Tears, known for its innovative autologous serum tears, is excited to announce the appointment...

read more
Vital Tears Names Joseph Tauber, MD as Chief Medical Officer
March 07, 2024
Telios Pharma's TL-925 Shows Promise in Dry Eye Disease Treatment

Telios Pharma, Inc. announced promising topline results from its Phase 2 study of TL-925, a pioneeri...

read more
Telios Pharma's TL-925 Shows Promise in Dry Eye Disease Treatment
March 07, 2024
Roche Pharma India Launches Vabysmo for AMD and DME

Roche Pharma India Ltd. has launched Vabysmo (faricimab) for the treatment of age-related macular de...

read more
Roche Pharma India Launches Vabysmo for AMD and DME
March 06, 2024
More